Luspatercept for transfusion-dependent β-thalassemia: time to get real
Ther Adv Hematol
.
2023 Aug 26:14:20406207231195594.
doi: 10.1177/20406207231195594.
eCollection 2023.
Authors
Khaled M Musallam
1
,
Sujit Sheth
2
,
Maria Domenica Cappellini
3
,
Antonis Kattamis
4
,
Kevin H M Kuo
5
,
Ali T Taher
6
Affiliations
1
Thalassemia Center, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
2
Division of Hematology and Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
3
Department of Clinical Sciences and Community, University of Milan, Ca' Granda Foundation IRCCS Maggiore Policlinico Hospital, Milan, Italy.
4
First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.
5
Division of Hematology, University of Toronto, Toronto, ON, Canada.
6
Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box 11-0236, Beirut, 11072020 - Lebanon.
PMID:
37645382
PMCID:
PMC10460678
DOI:
10.1177/20406207231195594
No abstract available
Keywords:
anemia; ineffective erythropoiesis; novel therapy; thalassemia; transfusion.
Publication types
Editorial